Explore the complete record of transactions filed by OSSER LEONARD, Director. Director active across 2 companies, notably Nexalin Technology, Inc.. In total, 41 reports have been logged. Total volume traded: €243k. The latest transaction was filed on 29 September 2025 — Attribution. Regulator: SEC (Form 4). The full history is openly available.
25 of 41 declarations
Leonard Osser is best known as a Director of Milestone Scientific, Inc., a company he founded in 1989. Public company materials show that he served in senior leadership roles at Milestone Scientific for many years, including as Chief Executive Officer. He was CEO from the company’s founding through 2007, and later returned to the role in September 2009 after stepping down as Chairman, a position he had held from 1991 to September 2009. More recently, Milestone Scientific states that he has served as a Director since December 2017, following a brief period as Managing Director – China Operations in 2017. He ceased serving as Chief Executive Officer in 2021. Overall, his background reflects long-term leadership experience in public-company governance and in the medical technology sector. Before Milestone Scientific’s public offering in 1995, Osser was primarily engaged as the principal owner and Chief Executive Officer of U.S. Asian Consulting Group, Inc., a New Jersey-based consulting firm focused on distressed and turnaround situations in both public and private markets. That earlier work points to a career built around strategic advisory, operational restructuring, and executive problem-solving. At Milestone Scientific, he helped guide the company through multiple phases of development over an extended period, contributing both as an executive and later as a board member. Nexalin Technology also identifies him as a member of its non-medical Board of Advisors and as Director of China operations, while noting that he serves as Managing Member of U.S. Asian Consulting Group LLC. Taken together, these disclosures suggest expertise in corporate leadership, turnaround consulting, cross-border business matters, and oversight of growth-stage and publicly traded healthcare-related companies.